Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy

Figures & data

Table 1 Age, follow-up, and distribution of cases according to surgical diagnosis

	Group 1 PPV	Group 2 Avastin + PPV	P value (w)	P value (chi)
Age, y, mean (SD)/(range)	46 (12)/(24–65)	44 (11)/(23–57)	0.7265
Indication of surgery, n (%)
TRD	4 (26.7)	4 (26.7)		1
TRD + vitreous Hge.	6 (40)	8 (53.3)		0.7152
Preretinal Hge.	2 (13.3)	1 (6.7)		1
Dense vitreous Hge.	3 (20)	2 (13.3)		1
Follow-up, mo., mean (SD)/(range)	11.7 (3.0)/(7–17)	12.9 (3.2)/(7–18)	0.2869

Abbreviations: SD, standard deviation; TRD, tractional retinal detachment; Hge, hemorrhage; Y, years; mo, months; PPV, pars plana vitrectomy; w, Wilcoxon two-sample test; chi, chi square test.

Figure 1 Fundus photographs of a case in group 2. A before injection of bevacizumab showing vitreous and subhyaloid hemorrhage and tractional retinal detachment. B 1 week after injection of bevacizumab showing evident regression of retinal neovascularization and C 12 months after vitrectomy with retina attached with near confluent laser marks.

Table 2 Intraoperative and postoperative data

	Group 1 PPV	Group 2 Avastin + PPV	P value (w)	P value (chi)
Bleeding frequency (times/surgery)
mean (SD)/(range)	6.8 (1.5)/(4–9)	1.9 (1.1)/(0–4)	<0.0001
Diathermy frequency (times/surgery)
mean (SD)/(range)	4.6 (1.2)/(2–6)	0.27 (0.46)/(0–1)	<0.0001
Surgical time (min.)
mean (SD)/(range)	93.3 (11.6)/(70–110)	61.6 (14.5)/(40–90)	<0.0001
PFCL use, n (%)	8 (53.3)	3 (20)
Relaxing retinotomy, n (%)	4 (26.6)	2 (13.3)
Endotamponade, n (%)
20% SF6	6 (40)	9 (60)
Air	0	3 (20)
Silicone oil	9 (60)	3 (20)
VA pre surgery
mean (± lines)/(range)	0.016 (6.2)/(HM −0.1)	0.01(7.3)/(HM −0.1)	P2 < 0.001
VA post surgery (final)			P = 0.52
mean (± lines)/(range)	0.12 (6.7)/(HM −0.5)	0.18 (6.8)/(HM −0.6)	P1 = 0.003
VA change, n (%)
Better	12 (80)	13 (86.6)
Same	2 (13.3)	2 (13.3)
Worse	1 (6.7)	0
Primary attachment, n (%)	13 (86.6)	14 (90.3)		1
Subsequent surgeries, n (%)
Cataract + oil removal	7 (46.7)	3 (20)
Re-PPV	2 (13.3)	1 (6.7)
Postoperative complications
Cataract, progressive	7 (46.7)	4 (26.6)
Cataract, gas-induced	2 (13.3)	3 (20)
Postoperative bleeding	4 (26.6)	0
Rubeosis	1 (6.7)	0
Optic pallor	0	1 (6.7)
Corneal erosions	5 (33.3)	2 (13.3)

Abbreviations: PPV, pars plana vitrectomy; VA, best corrected visual acuity; ww, Wilcoxon two-sample test; chi, chi square test; P1, preoperative versus final VA in group1; P2, preoperative versus final VA in group 2; P, p value, visual change between the two groups; SD, standard deviation; min, minutes; PFCL, perfluorocarbon liquid.